Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.

MLA

Mathé, G., et al. “Two Epipodophyllotoxin Derivatives, VM 26 and VP 16213, in the Treatment of Leukemias, Hematosarcomas, and Lymphomas.” Cancer (0008543X), vol. 34, no. 4, Oct. 1974, pp. 985–92. EBSCOhost, https://doi.org/10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U.

APA

Mathé, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., & De Vassal, F. (1974). Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer (0008543X), 34(4), 985–992. https://doi.org/10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U

Chicago

Mathé, G., L. Schwarzenberg, P. Pouillart, R. Oldham, R. Weiner, C. Jasmin, C. Rosenfeld, et al. 1974. “Two Epipodophyllotoxin Derivatives, VM 26 and VP 16213, in the Treatment of Leukemias, Hematosarcomas, and Lymphomas.” Cancer (0008543X) 34 (4): 985–92. doi:10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U.